Introduction: Daclatasvir is a non-structural protein 5A (NS5A) inhibitor with activity against hepatitis C virus (HCV) genotypes 1-6 in vitro, and asunaprevir is a non-structural protein 3 (NS3) protease inhibitor with activity against genotypes 1, 4, 5, and 6. This study evaluates potential options for the re-treatment Conclusion: Our in vitro results highlight a number of potential all-oral treatment options for patients who do not achieve a sustained virologic response following therapy with daclatasvir plus asunaprevir.
inhibitor with activity against HCV genotypes 1-6 in vitro [1] . Asunaprevir (ASV) is a nonstructural protein 3 (NS3) protease inhibitor with activity against genotypes 1, 4, 5, and 6 [2] . The all-oral, interferon-free combination of DCV ? ASV provided high rates of sustained virologic response and was well tolerated in genotype 1b-infected patients in global and Japanese Phase III studies [3, 4] . ASV ? BCV ? SOF were assessed initially using multiple EC 50 values of each agent estimated against wild-type replicon. RBV was examined at 1 9 EC 50 concentration, tenfold below any observed cell toxicity. In another approach, replicon cell lines were incubated without G418 for 1, 2, 3, 5 and 7 days with drug concentrations representing trough plasma concentrations (C trough ) observed in a clinical setting. In both approaches, the drug regimen was removed at the end of the incubation period and the cell cultures were further maintained for 2 weeks in growth medium supplemented with G418 (0.5 mg/mL) to monitor replicon elimination. Surviving replicon colonies were fixed and stained with crystal violet as described previously [10] .
RESULTS
Phenotypic analyses indicated that DCV ? ASVresistant replicon cell lines conferred high levels of resistance to DCV, LDV, ASV and SMV, relative to the wild-type reference replicon (Table 1) are provided in Supplementary Fig. 1 C trough trough plasma concentrations, EC 50 50% effective concentrations, GT genotype, NS3 non-structural protein 3, NS5A non-structural protein 5A, PI protease inhibitor, SD standard deviation * All EC 50 and C trough concentrations are nM, except for ribavirin (lg/mL) and peginterferon alfa (ng/mL) BMS data on file à Estimated value in eliminating wild-type replicons at 10 9 EC 50 values (Fig. 1a) Fig. 1 ). As expected, DCV ? ASV did not eliminate replicons harboring NS5A-L31M-Y93H and NS3-D168V, which confer reduced susceptibilities to both compounds (Fig. 1b) . (Table 1) . Monotherapy at C trough concentrations demonstrated the high potency of the NS5A inhibitors, DCV and LDV, compared with the other agents tested ( Fig. 2a ). With EC 50 values in the picomolar range that are well below the high plasma C trough concentrations obtained in clinical settings, treatment with these DAAs was sufficient in eliminating wild-type replicons within 7 days. Conversely, none of the NS5A inhibitors and NS3 protease inhibitors tested at C trough concentrations were able to eliminate DCV ? ASV-resistant replicons (Fig. 2b) . Moreover, SOF as a single agent exhibited low clearance activity in this assay. Although the C trough of SOF (1,100 nM) is higher than the EC 50 (147 nM), it is below the estimated SOF EC 90 (1,230 nM) . Furthermore, the metabolism and efficiency of phosphorylation of SOF appear to be lower in hepatoma cell lines compared with primary hepatocytes. An analysis of the mechanism of activation of SOF and its analogs has demonstrated that some enzymes in these metabolic pathways, such as CES1, are expressed at significantly lower levels in Huh7 Supplementary Fig. 1 . ASV asunaprevir, BCV beclabuvir, DCV daclatasvir, GT genotype, HCV hepatitis C virus, LDV ledipasvir, NS3 non-structural protein 3, NS5A nonstructural protein 5A, SMV simeprevir, SOF sofosbuvir ASV asunaprevir, BCV beclabuvir, C trough trough plasma concentrations, DCV daclatasvir, DMSO, dimethyl sulfoxide, GT genotype, HCV hepatitis C virus, LDV ledipasvir, NS3 non-structural protein 3, NS5A non-structural protein 5A, RBV ribavirin, SMV simeprevir, SOF sofosbuvir cells compared with primary hepatocytes [11] ; thus, the anti-HCV activity of SOF in repliconbased assays may not correlate with its activity in vivo. Similar instances of low activity with nucleosides in hepatoma-derived Huh7 cells harboring replicons have been reported [12, 13] . However, SOF has a high barrier to resistance and has demonstrated efficacy in combination regimens. For wild-type replicons, all DAA combinations at C trough concentrations that included an NS5A
inhibitor eliminated replicons with high efficiency (Fig. 2c) . In comparison, elimination of wild-type replicons was less efficient with SOF ? SMV and peginterferon alfa-based combinations ( Fig. 2c and Supplementary Supplementary Fig. 2 ).
DISCUSSION
In summary, these in vitro experiments demonstrate that there are a number of potential alternate all-oral DAA treatment options available for genotype 1b-infected patients who experience virologic escape during DCV ? ASV therapy. These include the three-DAA regimen of DCV ? ASV ? BCV combined with RBV or SOF, or other SOFbased combinations. Furthermore, the results suggest that a peginterferon alfa/RBV-based regimen with agents targeting NS5B could also provide effective therapy for these patients.
Results from this in vitro study will require further evaluation in clinical studies. The efficacy of re-treating patients who have failed prior boceprevir or telaprevir therapy with multiple DAAs (DCV ? SOF, SOF ? LDV) has already been demonstrated, with sustained virologic response rates of up to 99% achieved with 24 weeks of treatment [14, 15] . However, studies on the treatment of patients with resistance to multiple DAAs are more limited;
existing data suggest that effective options are available, and that it may also be possible to retreat patients with DAAs from the same drug class when combining with additional agents targeting complementary mechanisms of action [16] [17] [18] [19] . 
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